Report

Update: Detailed data on rolapitant presented

TESARO presented detailed data of three Phase III trials of rolapitant (one for patients receiving moderately emetogenic chemotherapy [MEC] and two for highly emetogenic chemotherapy [HEC]), which reinforced the differentiated attributes of the product compared to other products in the same class. The company also announced two planned Phase III trials of Niraparib, bringing the total Phase III programmes to four for this drug.
Underlying
TESARO Inc.

TESARO is an oncology-focused biopharmaceutical company. The company acquires, in-licenses and develops oncology product candidates. The company has in-licensed and is developing oncology-related product candidates, including rolapitant, niraparib, and the product candidates under its immuno-oncology platform. The company's existing products and product candidates are: Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an oral poly polymerase inhibitor for the treatment of ovarian or breast cancers; and Immuno-Oncology Platform, which is engaged in the discovery and development of antibodies for several immuno-oncology targets.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch